1424
trend, whereas efforts focused on appropriate community FQ use are likely of major importance. Larger, multicenter longitudinal studies focusing on the influence of active ASPs and restricted use of particular agents are critically important to better understanding how these interventions influence antimicrobial resistance patterns and how these policies can be applied for optimal effect.
Acknowledgments. We are grateful to the members of the antimicrobial stewardship committee for their continued support and dedication.
Financial support. No financial support was provided relevant to this article.
Conflicts of interest. All authors report no conflicts of interest relevant to this article.
References 1. Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med 2005;118:259–268.
2. Arizpe A, Reveles KR, Aitken SL. Regional variation in antibiotic prescribing among medicare part D enrollees, 2013. BMC Infect Dis 2016;16:744.
3. Bidell MR, Palchak M, Mohr J, Lodise TP. Fluoroquinolone and third- generation-cephalosporin resistance among hospitalized patients with urinary tract infections due to Escherichia coli: Do rates vary by hospital characteristics and geographic region? Antimicrob Agents Chemother 2016;60:3170–3173.
4. Scheld WM. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003;9:1–9.
5. Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002;162:2469–2477.
6. Ortega M, Marco F, Soriano A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic- resistant strain and their impact on the outcome. J Antimicrob Chemother 2009;63:568–574.
7. Peña C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escher- ichia coli in bloodstream infections. Antimicrob Agents Chemother 1995;39:520–524.
8. Huotari K, Tarkka E, Valtonen V, Kolho E. Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis 2003;22:492–495.
9. Camins BC, Marschall J, DeVader SR, Maker DE, Hoffman MW, Fraser VJ. The clinical impact of fluoroquinolone resistance in patients with E. coli bacteremia. J Hosp Med 2011;6:344–349.
10. Lautenbach E, Strom BL, Bilker WB, Patel JB, Edelstein PH, Fishman NO. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001;33:1288–1294.
11. Camins BC, King MD,Wells JB, et al. Impact of an antimicrobial utilization program on antimicrobial use at a large teaching hospital: a randomized controlled trial. Infect Control Hosp Epidemiol 2009;30:931–938.
12. Johannsson B, Beekmann SE, Srinivasan A, Hersh AL, Laxminarayan R, Polgreen PM. Improving antimicrobial stewardship: the evolution of programmatic strategies and barriers. Infect Control Hosp Epidemiol 2011;32:367–374.
13. Livermore DM, Hope R, Reynolds R, Blackburn R, Johnson AP, Woodford N. Declining cephalosporin and fluoroquinolone non- susceptibility among bloodstream Enterobacteriaceae from the UK: Links to prescribing change? J Antimicrob Chemother 2013;68:2667–2674.
14. Vernaz N, Huttner B, Muscionico D, et al. Modelling the impact of antibiotic use on antibiotic-resistant Escherichia coli using population- based data from a large hospital and its surrounding community. J Antimicrob Chemother 2011;66:928–935.
Rachael A. Lee et al
15. MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis 2005;41:435–440.
16. Gallini A, Degris E, Desplas M, et al. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia coli in a university hospital. J Antimicrob Chemother 2010;65:2650–2657.
17. Eom J-S, Hwang B-Y, Sohn J-W, et al. Clinical and molecular epidemiology of quinolone-resistant Escherichia coli isolated from urinary tract infection. Microb Drug Resist Larchmt 2002;8:227–234.
18. Sarma JB, Marshall B, Cleeve V, Tate D, Oswald T, Woolfrey S. Effects of fluoroquinolone restriction (from 2007 to 2012) on resistance in Enterobacteriaceae: interrupted time-series analysis. J Hosp Infect 2015;91:68–73.
19. Stapleton PJ, Lundon DJ, McWade R, et al. Antibiotic resistance patterns of Escherichia coli urinary isolates and comparison with antibiotic consumption data over 10 years, 2005–2014. Ir J Med Sci 2017;186:733–741.
20. Guo W, He Q, Wang Z, et al. Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008 to 2013 at a tertiary hospital in Shanghai, China. Am J Infect Control 2015;43:358–364.
21. Wong-Beringer A, Nguyen LH, Lee M, Shriner KA, Pallares J. An antimicrobial stewardship program with a focus on reducing fluoroqui- nolone overuse. Pharmacotherapy 2009;29:736–743.
22. Boel J, Andreasen V, Jarløv JO, et al. Impact of antibiotic restriction on resistance levels of Escherichia coli: a controlled interrupted time series study of a hospital-wide antibiotic stewardship programme. J Antimicrob Chemother 2016;71:2047–2051.
23. O’Brien KA, Zhang J, Mauldin PD, et al. Impact of a stewardship-initiated restriction on empirical use of ciprofloxacin on nonsusceptibility of Escherichia coli urinary isolates to ciprofloxacin. Pharmacotherapy 2015;35:464–469.
24. Wu H-H, Liu H-Y, Lin Y-C, Hsueh P-R, Lee Y-J. Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli. Wei Mian Yu Gan Ran Za Zhi (J Microbiol Immunol Infect) 2016;49:424–429.
25. Langford BJ, Seah J, Chan A, Downing M, Johnstone J, Matukas LM. Antimicrobial Stewardship in the microbiology laboratory: impact of selective susceptibility reporting on ciprofloxacin utilization and suscept- ibility of gram-negative isolates to ciprofloxacin in a hospital setting. J Clin Microbiol 2016;54:2343–2347.
26. White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25:230–239.
27. Cook PP, Das TD, Gooch M, Catrou PG. Effect of a program to reduce hospital ciprofloxacin use on nosocomial Pseudomonas aeruginosa susceptibility to quinolones and other antimicrobial agents. Infect Control Hosp Epidemiol 2008;29:716–722.
28. Dalhoff A. Global fluoroquinolone resistance epidemiology and implictions for clinical use. 2012;2012:976273.
Interdiscip Perspect Infect Dis
29. Thaden JT, Fowler VG, Sexton DJ, Anderson DJ. Increasing incidence of extended-spectrum β-lactamase-producing Escherichia coli in community hospitals throughout the southeastern United States. Infect Control Hosp Epidemiol 2016;37:49–54.
30. Gilbert DN, Kohlhepp SJ, Slama KA, et al. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob Agents Chemother 2001;45:883–892.
31. Bhavnani SM, Callen WA, Forrest A, et al. Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in US hospitals. Am J Health-Syst Pharm 2003;60:1962–1970.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124
